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Abstract.	  Feline	  infectious	  peritonitis	  (FIP)	  is	  associated	  with	  mutations	  in	  the	  feline	  coronavirus	  (FCoV)	  genome	  that	   are	   thought	   to	   convert	   the	   subclinical	   feline	   enteric	   coronavirus	   (FECV)	   into	   the	   lethal	   feline	   infectious	  peritonitis	  virus	  (FIPV).	  A	  key	  feature	  of	  FIPV,	  not	  shared	  with	  FECV,	  is	  the	  productive	  infection	  of	  macrophages.	  Therefore	  mutations	   in	  proteins	   that	  govern	  cell	   tropism,	  such	  as	   the	  spike	  glycoprotein,	  may	  play	  an	   important	  role	  in	  FIP	  progression.	  	  In	  a	  prior	  study,	  involving	  a	  limited	  number	  of	  samples,	  we	  have	  shown	  an	  association	  of	  FIP	   with	   mutations	   in	   the	   protease	   cleavage-­‐activation	   site	   located	   between	   the	   receptor-­‐binding	   and	   fusion	  domains	  of	  the	  FCoV	  spike	  (S1/S2).	  Here,	  we	  extend	  these	  studies	  to	  investigate	  a	  larger	  sample	  set	  and	  to	  obtain	  a	  more	  refined	  analysis	  of	  the	  mutations	  at	  this	  S1/S2	  site.	  Our	  larger	  data	  set	  more	  clearly	  shows	  that	  the	  mutations	  acquired	  by	  FIPV	  at	  S1/S2	  are	  also	  accompanied	  by	  additional	  mutations	  at	  a	  second	  protease	  cleavage-­‐activation	  site	  located	  in	  the	  fusion	  domain	  (S2’),	  adjacent	  to	  the	  viral	  fusion	  peptide.	  Overall,	  our	  data	  indicate	  a	  pattern	  of	  mutations	   across	   the	   two	   protease	   recognition	   sites	   that	   results	   in	   substitutions,	   and/or	   altered	   recognition,	   of	  critical	   basic/polar	   amino	   acid	   residues	   needed	   for	   virus	   activation	   in	   the	   enteric	   tract.	   Typically,	   FIPVs	   have	  substitutions	  of	  non-­‐polar,	   aliphatic	   or	   aromatic	   residues	   in	   the	  protease	   recognition	   sites.	  These	   changes	   likely	  modulate	  the	  proteolytic	  activation	  of	  the	  virus	  and	  its	  ability	  to	  productively	  infect	  macrophages	  in	  vivo.	  
Introduction	  Feline	   infectious	  peritonitis	   (FIP)	   is	  a	   fatal	   infection	  of	  cats	   caused	  by	  a	   feline	   coronavirus	   (FCoV)	   (11).	   FCoV	  infections	   are	   common,	   especially	   in	   high-­‐density	  housing	   situations	   such	   as	   animal	   shelters	   and	  breeding	   facilities.	   	   There	   are	   two	   biotypes	   of	   FCoV,	  classified	  as	  either	  feline	  enteric	  coronavirus	  (FECV)	  or	  feline	   infectious	   peritonitis	   virus	   (FIPV).	   The	   biotypes	  differ	   based	   on	   the	   severity	   of	   infection	   in	   cats.	  Typically,	   the	   FECV	   biotype	   of	   FCoV	   transmits	   readily	  via	   the	   fecal-­‐oral	   route,	   infects	   enterocytes	   in	   the	  gastrointestinal	   tract	   of	   cats,	   and	   causes	   only	   a	   mild	  infection.	   If	   the	   viral	   infection	   worsens	   and	   becomes	  systemic	   and	   lethal,	   then	   the	   virus	   is	   classified	   as	   the	  FIPV	   biotype.	   Symptoms	   associated	   with	   the	   FIPV	  biotype	   infection	   are	   granulomatous	   lesions,	   vascular	  leakage,	   and/or	   pleural	   and	   peritoneal	   effusion.	   The	  current	  understanding	  is	  that	  FIPV	  arises	  during	  in	  vivo	  infection	  due	  to	  genetic	  mutations	  of	  FECV	  (13,	  23,	  26,	  36).	   In	   approximately	  1-­‐5%	  of	   enteric	   infections,	   such	  spontaneous	   “internal	   mutation(s)”	   extend	   FCoV	  tropism	   to	   include	   blood	   monocytes	   and	   tissue	  macrophages	   (20).	   The	   resulting	   productive	   infection	  of	   these	   cells,	   a	   hallmark	   of	   FIP,	   enables	   systemic	  spread	   and	   results	   in	   macrophage	   activation,	   with	  concomitant	   immune-­‐mediated	   events	   leading	  ultimately	   to	   death.	   To	   date,	   the	   precise	   mutation(s)	  that	   account	   for	   a	   shift	   in	   the	   FCoV	   biotype	   have	   not	  
been	  identified	  and	  there	  is	  no	  definitive	  diagnostic	  test	  for	  FIP,	  except	   through	  post-­‐mortem	  histopathological	  analysis	  by	  immunocytochemistry.	  In	   addition	   to	   the	   two	   different	   biotypes	   (FECV	   and	  FIPV),	   two	   FCoV	   serotypes	   have	   been	   identified.	  Serotype	  1	  FCoVs	  are	  highly	  prevalent	  clinically	  (3,	  14,	  33),	   but	   do	   not	   propagate	   in	   cell	   culture	   and	   are	  therefore	   studied	   less	   often	   than	   serotype	   2	   FCoVs,	  which	  are	  easily	  propagated	  in	  vitro	  but	  not	  as	  clinically	  prevalent.	   In	   this	   study,	   we	   chose	   to	   study	   FECV	   and	  FIPV	  from	  serotype	  I	  FCoV.	  	  The	  FCoV	  genome	  is	  approximately	  29	  kB	  with	  11	  open	  reading	   frames	   encoding	   replication,	   structural,	   and	  accessory	   proteins	   (15).	   Like	   other	   RNA	   viruses,	  coronavirus	   replication	   is	   error	   prone,	   with	   an	  estimated	   mutation	   rate	   of	   approximately	   4×10-­‐4	  nucleotide	  substitutions/site/year	  (31,	  37).	  It	  has	  been	  suggested	   that	   mutations	   in	   the	   spike	   protein	   (S),	   3c,	  and/or	   7b	   genes	   are	   associated	  with	   the	   transition	   of	  FECV	   to	   FIPV	   (1,	   5-­‐7,	   19,	   22,	   24,	   28).	   Since	   the	   FCoV	  spike	   protein	  mediates	   receptor	   binding	   (through	   the	  S1	   subunit)	   and	   fusion	   (through	   the	   S2	   subunit),	   and	  mutations	   in	   the	   S	   gene	   allowed	   FCoV	   to	   infect	  macrophages	   (30),	   we	   focused	   on	   correlating	  mutations	   in	   this	   S	   gene	   with	   the	   biotype	   switch	   and	  changes	  in	  cellular	  tropism.	  	  The	   coronavirus	   spike	   protein	   (S)	   is	   a	   class	   I	   fusion	  protein,	  which	   typically	   requires	  activation	  by	   cellular	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proteases	  to	  be	  able	  to	  mediate	  cell	  entry.	  Mutation	  of	  the	   proteolytic	   cleavage	   sites	   can	   have	   profound	  implications	   for	   disease	   progression	   (4,	   16),	   and	  therefore	   we	   sought	   to	   determine	  whether	  mutations	  at	   protease	   cleavage	   sites	   are	   evident	   in	   the	   FIPV	  biotype.	  	  Proteases	  cleave	  their	  substrates	  though	  recognition	  of	  specific	   amino	   acid	  motifs	  within	   the	   relative	  position	  designation	   P6-­‐…-­‐P1	   |	   P1’-­‐…-­‐P6’,	   where	   cleavage	  occurs	   at	   the	   P1	   position,	   adjacent	   to	   the	   P1’	   position	  (27).	   In	   this	   paper,	   we	   will	   denote	   the	   cleavage	   site	  between	   P1	   and	   P1’	   using	   the	   vertical	   bar	   “|”	   symbol.	  For	   a	   typical	   serine	   protease	   like	   trypsin,	   there	   is	   a	  strong	  requirement	  for	  a	  basic	  amino	  acid	  (Arg	  or	  Lys)	  at	  the	  P1	  cleavage	  position.	  Substrate	  residues	  flanking	  P1	   can	   also	   have	   major	   impacts	   on	   the	   rate	   and	  specificity	  of	  cleavage	  for	  a	  given	  protease;	   in	  the	  case	  of	   influenza,	   the	   addition	   of	   arginine/lysine	   residues	  upstream	   of	   the	   P1	   residue	   (the	   polybasic	   region)	   of	  the	  viral	  HA	  can	  allow	  an	  alternate	  protease	  called	  furin	  to	   cleave	   HA	   and	   increase	   the	   virulence	   of	   this	   virus	  (25).	  	  Until	   recently,	  FCoVs	  were	   thought	   to	  use	  uncleaved	  S	  proteins	   to	   enter	   cells.	   However,	   a	   functional	   furin	  cleavage	   site	   has	   been	   identified	   in	   two	   examples	   of	  serotype	   1	   FECVs,	   located	   at	   the	   boundary	   of	   the	   S1	  and	   S2	   subunits	   (9).	   Furin	   is	   a	   ubiquitous	   proprotein	  convertase	   (PC)	   enriched	   in	   the	   trans-­‐Golgi	   network	  and	   is	   well	   conserved	   among	   mammals	   (32).	   Furin	  cleaves	   a	   wide	   range	   of	   protein	   precursors	   into	  biologically	  active	  products	  at	  a	  consensus	  motif	  that	  is	  often	   defined	   as	   R-­‐X-­‐K/R-­‐R,	   where	   R	   is	   the	   basic	  arginine	   residue,	   X	   is	   any	   residue,	   and	   K	   is	   the	   basic	  lysine	   residue	   (35).	   The	   minimum	   requirement	   for	  furin	  cleavage	  is	  for	  a	  P1	  and	  P4	  arginine.	  In	  addition	  to	  the	  P1-­‐P4	  arginines,	  these	  residues	  are	  often	  flanked	  by	  serine	   residues,	   and	   promoted	   by	   the	   presence	   of	   a	  basic	   residue	  at	  P2.	  The	  general	   cleavage	  requirement	  for	  a	  PC	  enzyme	   is	  defined	  as	  cleavage	  at	  paired	  basic	  residues	   (B-­‐X2n-­‐B),	  where	   the	   intermediate	   residues	   (-­‐X2n-­‐)	  consist	  of	  0,	  2,	  or	  4	  amino	  acids	  (32).	  For	  many	  enveloped	  viruses,	  protease	  cleavage	  occurs	  adjacent	   to	   the	   fusion	  peptide	  site,	  which	   is	   located	  at	  the	   boundary	   of	   the	   receptor-­‐binding	   and	   fusion	  domains	  of	  the	  envelope	  protein.	  For	  coronaviruses	  the	  fusion	  peptide	   is	   located	  within	  the	  fusion	  domains,	   in	  close	   proximity	   to	   second	   processing	   site	   denoted	   as	  S2’.	   The	   actual	   proteases	   that	   cleave	   at	   this	   site	   are	  currently	   unknown,	   but	   may	   include	   members	   of	   the	  cathepsin	   family	   that	   function	   in	   endosomes	   and	  lysosomes.	  Mutations	  at	   the	  S2’	   cleavage	   site	   could	  be	  
important	  and	   therefore	  we	  have	  chosen	   to	   study	   this	  site	  in	  addition	  to	  the	  S1/S2	  cleavage	  site.	  In	  this	  work,	  we	  used	  an	  approach	  to	  studying	  FIP	  that	  complements	  and	   extends	   previous	   work.	   We	   focused	   on	   sequence	  analysis	   of	   the	   two	   cleavage-­‐activation	   sites	   of	   the	  spike	   gene	   (S1/S2	   and	   S2’),	   which	   are	   functionally	  relevant	  regions	  for	  virus	  entry	  and	  infection.	  To	  obtain	  FECV	   gene	   samples,	   fecal	   material	   from	   healthy	   cats	  that	  carried	  FCoV	  was	  sequenced	  for	  the	  S	  gene.	  These	  gene	  samples	  were	  operationally	  defined	  as	  being	  from	  the	  FECV	  biotype,	  and	  56	  FECV	  samples	  were	  obtained	  in	   this	  study.	  To	  obtain	  FIPV	  samples,	   tissue	  and	  body	  fluid	   samples	   were	   collected	   from	   cats	   that	   were	  diagnosed	   with	   FIP.	   For	   tissue	   samples,	   cats	   were	  typically	   euthanized	   based	   on	   a	   clinical	   diagnosis	   of	  FIP,	   and	   samples	   were	   collected	   post-­‐euthanasia.	   In	  many	   cases,	   a	   diagnosis	   of	   FIP	   was	   reconfirmed	   by	  immunohistochemistry	   (IHC)	   of	   tissue	   from	   the	  euthanized	  cats,	  but	  not	  all	  samples	  were	  examined	  by	  IHC	   for	   logistical	   reasons.	   Viral	   gene	   sequences	  obtained	   from	   FIP	   cats	   were	   operationally	   defined	   as	  being	   from	   the	   FIPV	   biotype.	   In	   this	   study,	   84	   FIPV	  samples	   were	   sequenced	   from	   39	   cats	   and	   various	  organs	   and	   tissues.	   Samples	   from	   our	   previous	   study	  (19)	  were	  also	   included	  to	  provide	  as	  complete	  a	  data	  set	  as	  possible,	  and	  we	  compared	  our	  data	  to	  those	  of	  a	  separate	   study	   by	   Chang	   et	   al.	   (6).	   Our	   studies	   were	  consistent	  with	   the	   hypothesis	   that	  mutations	   in	   both	  the	  S1/S2	  and	  S2’	  protease	  cleavage	  sites	  were	  present	  in	  FIPV	  samples.	  	  
Methods	  
FCoV	   sample	   acquisition	   and	   sequence	   analysis.	   Fecal	  samples	   from	   subclinically	   infected	   cats	   and	   tissue	  samples	  from	  cats	  with	  a	  clinical	  diagnosis	  of	  FIP	  were	  solicited	   from	   shelters,	   breeders	   and	   veterinarians	  throughout	   the	   United	   States.	   To	   initially	   confirm	  samples	  were	  FCoV-­‐positive,	  RNA	  was	  extracted	  using	  QIAamp	   Viral	   RNA	   Mini	   (Qiagen,	   Valencia,	   CA)	   and	  FCoV	  primers	  that	  detect	  most	  circulating	  strains	  were	  used	   to	   screen	   all	   fecal	   samples	   using	   the	   procedure	  outlined	   by	   Herrewegh	   and	   coworkers	   (12).	   RNA	  extracted	   from	   the	   FIPV-­‐TN406/Black	   lab-­‐adapted	  strain	   was	   used	   as	   positive	   control.	   Fresh	   tissue	  samples	   from	   FIP-­‐diagnosed	   cats	   were	   harvested	   and	  RNA	   samples	   were	   extracted	   using	   MagMAX	   Express	  (Life	  Technologies,	  Grand	  Island,	  NY).	  For	  all	  samples	  that	  were	  FCoV-­‐positive,	  50	  μL	  RT-­‐PCR	  reactions	   were	   performed	   with	   One-­‐Step	   RT-­‐PCR	  (Qiagen,	   Valencia,	   CA)	   using	   gene-­‐specific	   S	   primers,	  encompassing	  S1/S2	  and	  S2’:	  S1/S2	  primer	  pair	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5'-­GCACAAGCAGCTGTGATTA-­‐3'	   and	   5'-­GTAATAGAATTGTGGCAT-­3';	   S2'	   primer	   pair	   5'-­GATATGATCACAGTATCAGATCG	   -­3'	   and	   5'-­‐ATAATC	  ATCATCAACAGTGCC-­3'.	   PCR	   conditions	   were:	   30	   min	  at	  50°C,	  15	  min	  at	  95°C,	  and	  39	  or	  35	  cycles	  of:	  1	  min	  at	  94°C,	   1	   min	   at	   55°C,	   1	   or	   1.5	  min	   at	   72°C,	   10	  min	   at	  72°C.	   PCR	   products	   were	   purified	   using	   Qiaquick	   Gel	  Extraction	   (Qiagen,	   Valencia,	   CA).	   Sanger-­‐based	   di-­‐deoxy	   sequencing	  was	   performed	   at	   the	   Life	   Sciences	  Core	  Laboratories	  (Cornell	  University).	  DNA	  sequences	  were	  translated	  into	  protein	  sequences	  and	  alignments	  were	   performed	   using	   Geneious	   5.4	  (http://www.geneious.com).	  
Visual	   Representation	   of	   Mutation	   Data.	   	   	  To	   visualize	  the	  biochemical	  changes	   in	  the	  protease	  cleavage	  sites	  of	  the	  S	  protein,	  we	  developed	  a	  specialized	  scatter	  plot	  through	  MATLAB	  [MathWorks,	  Natick,	  MA].	  A	  separate	  plot	   was	   made	   for	   each	   residue	   position	   being	  evaluated,	   and	   the	   Van	   der	   Waals	   (VdW)	   volume	   of	  amino	  acids	  (29)	  was	  plotted	  against	  their	  hydropathy	  index	   (HPI)	   (18).	   In	   general,	   amino	   acids	   with	   lower	  HPI	   are	   more	   hydrophilic	   whereas	   those	   with	   higher	  HPI	   are	   more	   hydrophobic.	   Each	   data	   point	  corresponds	   to	   an	   amino	   acid	   that	   was	   found	   at	   the	  residue	   position	   being	   evaluated,	   and	   the	   size	   of	   the	  data	   point	   scales	  with	   the	   frequency	   of	   occurrence	   of	  that	  amino	  acid	  within	  a	  data	  set.	  We	  caution	  here	  that	  the	   data	   point	   size	   does	   not	   denote	   an	   error	   range	   in	  VdW	  volume	  or	  HPI.	  Other	  important	  properties	  of	  the	  amino	   acids	   were	   portrayed	   by	   color-­‐coding	   the	   data	  points	   as	   such:	   polar	   positive	   (blue:	   H,K,R),	   polar	  negative	   (red:	   D,E),	   polar	   neutral	   (green:	   S,T,N,Q),	  nonpolar	  aliphatic	  (gray:	  A,V,L,I,M),	  nonpolar	  aromatic	  (magenta:	   F,W,Y),	   unique	   (brown:	   P,G),	   and	   disulfide	  bond-­‐forming	  (cyan:	  C).	  	  
Results	  and	  Discussion	  
FECV	  sequence	  from	  healthy	  cats	  The	  amino	  acid	  sequence	  motifs	   for	   the	  S1/S2	  and	  S2’	  regions	   are	   shown	   in	  Table	  1.	   	   For	   the	   S1/S2	   site,	   the	  previously	   recognized	  motif	   -­‐R-­‐R-­‐S/A-­‐R-­‐R-­‐S-­‐	   (19)	  was	  again	  found	  to	  be	  highly	  conserved.	  There	  was	  a	  limited	  variability	   in	  the	  P5	  position,	  with	  Arg	  substituted	  for:	  Gly	  (1	  cat)	  and	  Lys	  (1	  cat).	  The	  functional	  relevance	  of	  this	  variation	   is	  unclear,	   though	   the	  P5	  position	   is	  not	  generally	   considered	   to	   be	   highly	   important	   for	   furin	  cleavage.	  There	  was	  also	  a	  single	  case	  with	  a	  change	  in	  the	  P3	  position	  with	  Ser/Ala	  substituted	  for	  Val	  (1	  cat).	  As	   with	   P5,	   the	   type	   of	   amino	   acid	   residue	   at	   the	   P3	  position	   is	   not	   functionally	   critical	   for	   furin	   cleavage.	  Based	   on	   the	   expanded	   dataset	   available	   from	   this	  
study,	  we	   also	   noted	   a	   high	   degree	   of	   conservation	   at	  the	   P6	   cleavage	   position	   (which	   can	   be	   highly	  important	   for	   furin	   cleavage).	  All	   samples	   contained	   a	  polar	  uncharged	  residue	  (S,	  T	  or	  Q)	  at	  the	  P6	  position.	  Overall,	   the	   expanded	   data	   set	   reinforces	   the	   notion	  that	   the	   S1/S2	  motif	   is	   cleaved	  by	   furin.	  Based	  on	   the	  data	   from	   this	   study,	   we	   consider	   to	   following	   as	   an	  “FECV”	  motif	  at	  the	  S1/S2	  position:	  -­‐S/T/Q-­‐R-­‐R-­‐S/A-­‐R-­‐R-­‐S-­‐	  At	  the	  S2’	  site,	  the	  conserved	  nature	  of	  the	  FCoV	  fusion	  peptide	   (SAVEDLLF)	  was	   readily	   apparent,	   along	  with	  the	   expected	   conserved	   arginine	   residue	   in	   the	   P1	  cleavage	   position	   (Table	   1).	   All	   FECV	   samples	   tested	  contained	   a	   P2	   lysine,	   with	   the	   high	   level	   of	  conservation	   implicating	   this	   as	   a	   functionally	   critical	  residue.	  The	  P1’	  residue	  (S)	  was	  also	  100%	  conserved,	  consistent	  with	  a	  role	  in	  protease	  cleavage,	  as	  well	  as	  in	  fusion	  peptide	  function.	  Overall,	  we	  found	  an	  invariant	  motif	   -­‐K-­‐R-­‐S-­‐	   at	   the	   S2’	   position	   of	   FECV,	   and	   the	  dibasic	  nature	  of	  this	  site	  is	  consistent	  with	  cleavage	  by	  a	   range	   of	   proteases,	   including	   non-­‐furin	   PCs	   and	  cathepsin	  B.	  
FIPV	  sequence	  from	  FIP	  cats	  The	  amino	  acid	  sequence	  motifs	   for	   the	  S1/S2	  and	  S2’	  regions	   in	  the	  FCoV	  spike	  gene	  amplified	  from	  various	  tissues	   and	   body	   fluid	   samples	   are	   shown	   in	   Table	   2.	  For	  S1/S2,	   the	  FECV	  motif	   -­‐S/T/Q-­‐R-­‐R-­‐S/A-­‐R-­‐R-­‐S-­‐	  was	  disrupted	   in	   the	   vast	  majority	  of	   samples.	   In	   addition,	  the	   S2’	   FECV	   -­‐K-­‐R-­‐S-­‐	   motif	   was	   disrupted	   in	   many	  samples.	  Fecal	  material	  from	  FIP	  cats	  is	  shown	  in	  Table	  3,	  with	  sequences	  very	  similar	  to	  FECV	  samples.	  For	   S1/S2,	   we	   focused	   our	   analysis	   on	   the	   “core”	  residues	   for	   furin	   cleavage,	   i.e.	   the	   P1’,	   P1,	   P2	   and	   P4	  residues.	  The	  most	  frequent	  substitution	  was	  at	  the	  P1	  position,	  where	   11	   cats	   displayed	   a	   change	   of	   Arg	   for	  Gly	  (4	  cats),	  Met	  (4	  cats),	  Trp	  (2	  cats),	  Thr	  (1	  cat)	  and	  Ser	  (1	  cat).	  The	  next	  most	  frequent	  substitution	  was	  at	  the	   P2	   position,	   where	   10	   cats	   displayed	   a	   change	   of	  Arg	  for	  Leu	  (6	  cats),	  Pro	  (3	  cats),	  Ser	  (1	  cat)	  and	  His	  (1	  cat).	   Five	   cats	   had	   a	   substitution	   at	   the	   P4	   position,	  which	  displayed	  a	  change	  of	  Arg	  for	  Thr	  (2	  cats)	  Gly	  (1	  cat),	   Ser	   (1	   cat),	   and	   Met	   (1	   cat).	   Four	   cats	   had	   a	  substitution	   at	   the	   P1’	   position,	   which	   displayed	   a	  change	   of	   Ser	   for	   Ala	   (2	   cats)	   Pro	   (1	   cat),	   Gly	   (1	   cat),	  and	   Leu	   (1	   cat).	   	   All	   of	   these	   changes	   in	   the	   core	  residues	   would	   be	   expected	   to	   be	   highly	   functionally	  significant	  for	  furin	  cleavage.	  At	   the	   S2’,	   the	   conserved	  nature	   of	   the	   fusion	   peptide	  (SAVEDLLF)	  was	  again	  readily	  apparent,	  along	  with	  an	  invariant	  Ser	  at	   the	  P1’	  position	  (Table	  2).	  While	  most	  
Mutations	  in	  feline	  coronavirus	  spike	  protein	  cleavage-­activation	  sites	  in	  cats	  with	  FIP	  
	   4	  
FIPV	   cats	   contained	   a	   P1	   arginine,	   three	   cats	   had	  substitutions	  for	  Ser.	  This	  change	  would	  be	  expected	  to	  be	  highly	  functionally	  significant	  for	  protease	  cleavage.	  There	  were	  more	  substitutions	   in	  the	  P2	  residue,	  with	  five	  cats	  displaying	  a	  change	  of	  Lys	  for	  Met	  (3	  cats)	  and	  Glu	   (2	  cats).	  These	  changes	  would	  also	  be	  expected	   to	  be	  highly	  functionally	  significant	  for	  protease	  cleavage.	  The	  overall	   switch	   in	   the	  dibasic	  nature	  of	   the	  S2’	   site	  in	   some	   cats	   is	   consistent	   with	   a	   change	   in	   the	  protease(s)	  cleaving	  at	  this	  position.	  For	  the	  core	  residues	  at	  S1/S2	  and	  S2’.	  31	  out	  of	  39	  FIP	  cats	   (77%)	   had	   samples	   that	   were	  modified	   from	   the	  FECV	   consensus	   (-­‐S/T/Q-­‐-­‐R-­‐R-­‐S/A-­‐R-­‐R-­‐S-­‐).	   Healthy	  cats	  showed	  no	  deviation	  from	  the	  core	  motif	  The	   P6,	   P5	   and	   P3	   residues	   within	   the	   S1/S2	   site	   (-­‐	  S/T/Q-­‐-­‐R-­‐R-­‐S/A-­‐R-­‐R-­‐S-­‐)	   were	   defined	   as	   “non-­‐core”	  residues	   as	   these	   are	   likely	   to	   be	   less	   functionally	  relevant	  for	  furin	  cleavage.	  Of	  these	  residues,	  P6	  likely	  impacts	   furin	   cleavage	   the	   most.	   For	   the	   P6	   position,	  five	  cats	  displayed	  a	  change	  of	  Ser/Thr/Gln	   for	  Pro	   (2	  cats),	   Phe	   (1	   cats),	   Ala	   (1	   cat)	   and	   Leu	   (1	   cat).	   All	   of	  these	   changes	   would	   be	   expected	   to	   be	   functionally	  significant	  for	  furin	  cleavage.	  	  Including	  S1/S2	  P6	  as	  a	   core	   residue	   revealed	   that	  33	  out	   of	   39	   FIP	   cats	   (85%)	   had	   samples	   that	   were	  modified	  from	  the	  FECV	  consensus	  (-­‐S/T/Q-­‐R-­‐R-­‐S/A-­‐R-­‐R-­‐S-­‐).	   Healthy	   cats	   showed	   no	   deviation	   from	   a	   core	  motif	  including	  P6.	  For	  the	  non-­‐core	  S1/S2	  P5	  position,	  nine	  cats	  displayed	  a	  change	  of	  Arg	   for	  Lys	  (8	  cats),	  as	  seen	   for	  FECV.	  For	  the	   non-­‐core	   S1/S2	   P3	   position,	   two	   cats	   displayed	   a	  change	  of	  Ser/Ala	  for	  Met	  (1	  cats)	  and	  Thr	  (1	  cat).	  The	  significance	  of	  these	  changes	  is	  uncertain.	  The	  S2’	  non-­‐core	  P1’	   residue	   showed	  no	  deviation	   in	   either	   FIP	  or	  healthy	  cats.	  Including	   both	   core	   and	   non-­‐core	   residues	   at	   S1/S2	  and	   S2’,	   we	   found	   that	   37/39	   FIP	   cats	   (95%)	   had	  mutations	  compared	  to	  healthy	  cats.	  9%	  of	  healthy	  cats	  showed	  a	  mutation	  within	  the	  non-­‐core	  residues	  It	   is	   noteworthy	   that	  many	   cats	   had	  multiple	   changes	  across	   the	   two	   proteolytic	   cleavage	   sites	   and	   while	  there	   was	   a	   wide	   variety	   of	   different	   substitutions	  present	   in	   different	   cats,	   sampling	   of	   multiple	   tissues	  within	   an	   individual	   cat	   (e.g.	   cat#197)	   revealed	  relatively	   limited	   variation.	   It	   is	   also	   noteworthy	   that	  most	   of	   our	   samples	   would	   be	   expected	   to	   be	  comprised	   of	   “end-­‐stage”	   viruses,	   where	   cats	   have	  more	  obvious	  clinical	  signs	  of	  FIP.	  It	  will	  be	  interesting	  to	   track	  cats	   that	  might	  be	   in	  an	   “early”,	  possibly	   sub-­‐clinical,	   phase	   of	   FIP.	   These	   cats	   may	   harbor	   viruses	  
that	   have	   different	   mutations	   to	   end-­‐stage	   viruses	  sampled	  here,	  in	  particular	  in	  the	  “non-­‐core”	  residues.	  While	  a	  prediction	  of	  the	  proteases	  coming	  into	  play	  for	  FIPV	  is	  quite	  uncertain,	  the	  trend	  in	  our	  data	  is	  for	  the	  replacement	   of	   critical	   basic	   residues	   and	   serine	  with	  more	   hydrophobic	   residues,	   a	   pattern	   consistent	  with	  cleavage	  by	  an	  alternative	  protease(s).	   Such	  proteases	  may	  include	  cathepsins	  (8),	  or	  matrix	  metalloproteases	  (MMPs)	  (17).	  MMPs	  are	  known	  to	  be	  highly	  expressed	  on	   macrophages	   (2)	   and	   to	   our	   knowledge,	   MMP-­‐mediated	  cleavage	  of	  a	  viral	  envelope	  protein	  would	  be	  unique	  situation	  for	  a	  virus	  entry	  pathway.	  Both	  MMPs	  and	   cathepsin	   demonstrate	   relatively	   broad	   substrate	  specificity,	   in	   line	  with	   the	   range	  of	  mutations	   seen	   in	  the	  cleavage	  site(s)	  of	  FIPVs.	  
Comparison	  to	  a	  separate	  study	  (Chang	  et.	  al.	  2012)	  
and	  to	  database	  sequences	  The	  data	  generated	  during	  the	  course	  of	  our	  study	  was	  compared	  to	  that	  generated	  by	  a	  separate	  study,	  Chang	  
et	   al.	   2012	   (6),	   as	   well	   as	   to	   additional	   database	  sequences	   (Table	   4).	   For	   S1/S2,	   of	   the	   ten	   FECV	  sequences	   in	   Chang	   et	   al.,	   the	   -­‐Q/R/S-­‐R-­‐R-­‐S/A-­‐R-­‐R-­‐S-­‐	  motif	  was	  preserved	  with	  one	  exception,	  where	  one	  cat	  had	   a	  P6	  Pro	   residue.	  All	   core	   residues	  were	   identical	  to	   our	   study.	   A	   P6	   Pro	   was	   also	   found	   in	   one	   other	  database	   sequence.	   The	   pattern	   of	   residues	   in	   FIPV	  samples	   followed	   the	   same	   general	   pattern	   as	  described	   for	  our	   study;	   i.e.	   introduction	  of	  non-­‐polar,	  aliphatic	   or	   aromatic	   residues	   in	   the	   protease	  recognition	   sites.	   	   Of	   the	   eleven	   FIP	   cats	   samples	   in	  Chang	  et	  al.	  2012,	  four	  had	  P1	  substitutions	  (G,	  W	  and	  S),	   two	   had	   P1’	   substitutions	   (L	   and	   P),	   two	   had	   P4	  substitutions	  (G	  and	  S),	  and	  three	  had	  P6	  substitutions	  (L	   and	   P).	   Of	   seven	   database	   samples,	   three	   had	   P1	  substitutions	   (G,	  W	   and	   S),	   two	   had	   P1’	   substitutions	  (P),	   one	   had	   P4	   substitutions	   (Q),	   and	   five	   had	   P6	  substitutions	  (A	  and	  P).	  At	  S2’,	  Chang	  et	  al.	  2012	  show	  some	  limited	  changes	  of	  the	   invariant	   KRS	   motif	   for	   FECV,	   with	   different	   P2	  residues	  in	  four	  cats,	  substituted	  with	  Arg	  (3	  cats)	  and	  Thr	  (1	  cat).	  Cats	  with	  FIP	  showed	  an	   introduction	  of	  a	  hydrophobic	   reside	  at	  P2	   in	   five	   cases,	  with	  Lys	  being	  substituted	   for	  Met	   (4	   cats)	   and	   Val	   (1	   cat).	   A	   similar	  trend	   was	   present	   in	   database	   samples,	   with	  introduction	   of	   Val,	   Ala	   and	   Gln	   in	   three	   individual	  cases.	  Overall,	   we	   consider	   that	   the	   data	   from	   Chang	   et	   al.	  2012,	   as	   well	   as	   other	   database	   sequences,	   are	   in	  strong	  agreement	  with	  the	  data	  from	  this	  study.	  10/11	  (91%)	   of	   samples	   from	   Chang	   et	   al	   2012.	   and	   4/4	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(100%)	   of	   database	   samples	   had	   functionally	  significant	  mutations	  in	  the	  spike	  cleavage	  sites.	  
Visual	  representation	  of	  sequences	  in	  the	  protease	  
activation	  sites	  of	  FECV	  and	  FIPV	  spike	  proteins	  Finding	   a	   mutation	   pattern	   that	   could	   explain	   the	  transformation	  of	  FECV	  to	  FIPV	  is	  challenging	  because	  amino	   acids	   have	  multiple	   properties	   that	   are	   similar	  or	   dissimilar	   with	   each	   other,	   such	   as	  molecular	   size,	  hydrophobicity,	   and	   charge	   (34).	   In	   order	   to	  simultaneously	   visualize	   changes	   to	   multiple	  biochemical	   properties,	   we	   developed	   a	   specialized	  scatter	   plot	   through	  MATLAB	   that	   shows	   the	   Van	   der	  Waals	   volume	   (Y-­‐axis),	   hydropathy	   index	   (X-­‐axis),	  frequency	   of	   occurrence	   (data	   point	   size),	   and	   unique	  property	   (color	   code)	   of	   amino	   acids	   found	   at	   the	  cleavage	   site	   positions.	   The	   resulting	   plots	   are	   shown	  in	   Figure	   1	   for	   the	   residues	   at	   the	   S1/S2	   and	   S2’	  cleavage	  sites	  for	  both	  the	  FECV	  and	  FIPV	  samples.	  	  Compared	   to	   FECV,	   FIPV	   contains	   the	   following	  changes	  in	  the	  S1/S2	  cleavage	  site:	  P6	  and	  P1’	  mutates	  from	   polar	   neutral	   residues	   to	   nonpolar	   residues,	   P4	  and	   P2	   mutates	   from	   arginine	   to	   smaller	   and	   more	  hydrophobic	  residues,	  and	  P1	  mutates	  from	  arginine	  to	  more	   hydrophobic	   residues.	   At	   the	   S2’	   cleavage	   site,	  FIPV	   contains	   the	   following	   mutations:	   P2	   mutates	  from	   positively	   charged	   lysine	   to	   either	   negatively	  charged	   glutamate	   or	   uncharged	   methionine,	   and	   P1	  mutates	   from	   positively	   charged	   arginine	   to	   polar	  neutral	   serine	   that	   is	   half	   the	   volume	   of	   arginine.	   In	  summary,	   the	   visualization	   of	   biochemical	   changes	   at	  the	  cleavage	  sites	  using	  our	  plotting	  method	  can	  greatly	  aid	   with	   the	   identification	   of	   mutation	   patterns	  associated	  with	  FIP.	  
Potential	  use	  of	  this	  study	  for	  diagnosis	  of	  FIP	  in	  cats	  We	   believe	   that	   our	   study	   will	   be	   of	   benefit	   in	   the	  diagnosis	   of	   FIP	   in	   cats	   by	   detecting	   mutations	   in	   S	  protein	   cleavage	   site	   that	   mimic	   those	   found	   in	   FIPV.	  However,	  the	  pattern	  of	  variant	  viruses	  seen	  in	  FIP	  cats	  is	   complex.	   We	   consider	   that	   the	   tracking	   of	   the	   ten	  amino	   acids	   that	   comprise	   the	   cleavage	   sites	   of	   FCoV	  spike	   (-­‐S/T/Q-­‐R-­‐R-­‐S/A-­‐R-­‐R-­‐S-­‐	   from	  S1/S2	   and	   -­‐K-­‐R-­‐S-­‐	  from	   S2’)	  with	   respect	   to	   the	   biochemical	   parameters	  of	   size,	   hydrophobicity,	   and	   charge	   can	   be	   used	   to	  predict	   the	   likelihood	   of	   FIP	   in	   cats.	   To	   simplify	   the	  detection	  of	  FIPV-­‐like	  mutations,	  one	  could	  potentially	  use	   the	   changes	   in	   these	   biochemical	   parameters	   in	  conjunction	   with	   a	   ranking	   of	   the	   core	   and	   non-­‐core	  residues	   to	   arrive	   at	   a	   “FIP	   diagnostic	   score.”	   Such	   a	  scoring	  system	  could	  help	  clinicians	  identify	  which	  cats	  are	   likely	   to	   develop	   FIP	   without	   the	   need	   to	  functionally	   investigate	  every	  mutation	  found.	  The	  use	  
of	   this	   scoring	   metric	   for	   samples	   that	   clinicians	   can	  easily	   access	   (e.g.	   blood)	   would	   be	   helpful	   for	  diagnosing	   FIP	   early	   and	   quickly.	   While	   our	   current	  study	  only	  utilized	  a	  limited	  number	  of	  blood	  samples,	  mutations	  consistent	  with	  a	  FIPV	  biotype	  were	  seen	  in	  all	   positive	   samples.	   However,	   it	   is	   known	   that	   FCoV	  can	  be	  present	   in	   the	  blood	  monocytes	  of	  healthy	  cats	  without	  necessarily	  leading	  to	  FIP	  (10,	  12,	  28).	  Further	  investigation	   into	   the	   spike	   protein	   cleavage	   site	  changes	   in	  blood	  samples	  of	  both	  healthy	  and	  FIP	  cats	  will	  form	  a	  future	  focus	  of	  this	  study.	  We	   considered	   that	   fecal	   samples	   from	   FIP	   cats	   were	  likely	   to	   be	   contaminated	   with	   an	   ongoing	   infection	  with	  FECV,	  and	  so	  not	  discriminatory	  for	  FIP.	  This	  was	  confirmed,	   as	   the	   FIP	   cats	   tested	   in	   this	   study	  continued	   to	   shed	   FECV-­‐like	   viruses,	   based	   on	   the	  highly	  limited	  sequence	  variation	  observed	  at	  the	  spike	  cleavage	  sites	  (Table	  3).	  	  FIP	  exists	   in	   two	  clinical	  manifestations	  (wet	  and	  dry)	  (21).	   As	   in	   our	   previous	   study	   (19),	   we	   found	   no	  correlation	   between	   sequence	   alterations	   at	   the	   spike	  cleavage	  sites	  between	  “wet”	  and	  “dry”	  FIP	  cats.	  These	  differences	  in	  clinical	  presentation	  are	  likely	  to	  be	  due	  to	  immunological	  factors	  in	  individual	  cats,	  rather	  than	  differences	   in	   the	   cleavage-­‐activation	   of	   the	   viruses	  infecting	  these	  cats.	  The	  use	  of	  the	  techniques	  reported	  here	  for	  serotype	  I	  FCoVs	   may	   also	   be	   applied	   to	   serotype	   II	   FCoVs;	  however,	  these	  viruses	  lack	  an	  equivalent	  S1/S2	  motif.	  Investigation	  of	  predictive	  changes	  in	  the	  S2’	  region	  of	  serotype	  II	  FCoVs	  is	  currently	  ongoing.	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TABLE	  1	  	  	  	  Amino	  acid	  sequences	  in	  the	  S1/S2	  and	  S2'	  regions	  of	  the	  FCoV	  spike	  obtained	  from	  fecal	  samples	  from	  heathly	  cats.	  	  The	  ten	  amino	   acids	   comprising	   the	   predicted	   proteolytic	   cleavage	   sites	   are	   in	   bold,	   with	   modifications	   to	   these	   residues	   colored	  (green	  =	  modification	  to	  non-­‐core	  residue).	  	  	  
Cat ID Sample       S1/S2 S2' 
150 Feces     TSSRRSRRSTTE HSIGKRSAVED 
106 Feces    TQSRRSRRSYPD PTIGKRSAVED 
110 Feces    TQTRRSRRSTSE  PRIGKRSAVED 
111 Feces    THSRRARRSTVE  PRIGKRSAVED 
125 Feces    TQSRRARRSTVE PTIGKRSAVED 
126 Feces    TQSRRSRRSASS PTIGKRSAVED 
128 Feces    THSRRARRSTVE PTIGKRSAVED 
129 Feces    TQSRRSRRSTSD  PTIGKRSAVED 
131 Feces    TQSRRSRRSASN PTIGKRSAVED 
132 Feces    TQSRRSRRSAPE PRIGKRSAVED 
135 Feces    TQSRRARRSLPA  PRIGKRSAVED 
136 Feces    TQSRRSRRSVVE  PQIGKRSAVED 
137 Feces    TSSRRSRRSTPE  HSIGKRSAVED 
138 Feces    TQSRRSRRSVAE  PTIGKRSAVED 
140 Feces    TQSRRSRRSVVE  PTIGKRSAVED 
141 Feces    TQSRRSRRSVVE PQIGKRSAVED 
142 Feces    THSRRARRSTVE PTIGKRSAVED 
143 Feces    TSSRRARRSSVE  PTIGKRSAVED 
144 Feces    TQSRRSRRSASM PTIGKRSAVED 
146 Feces    THSRRARRSTVE PKIGKRSAVED  
149 Feces     TSSRRSRRSTPE  HSIGKRSAVED 
150 Feces VNHTSSRRSRRSTTET HSIGKRSAVED 
152 Feces    THSRRSRRSNSD  PRIGKRSAVED 
153 Feces    PHSRRSRRSTNY PTIGKRSAVED 
155 Feces    TQSGRSRRSASD not determined 
160 Feces  NHTHSKRSRRSTSN PTIGKRSAVED 
167 Feces    THSKRSRRSTSN PTIGKRSAVED 
234.1 Feces    THTRRSRRSAPV PTIGKRSAVED 
246 Feces  NHTQSKRSRRSAPH PKIGKRSAVED 
304 Feces    THTRRSRRSAPV PTIGKRSAVED 
307 Feces    THTRRSRRSAPV PTIGKRSAVED 
308 Feces  NHTHTRRSRRSAPI PKIGKRSAVED 
308 Feces    THTRRSRRSAPI PTIGKRSAVED 
310 Feces    THTRRSRRSAPA PTIGKRSAVED 
313 Feces   HARTRRSRRSAPV PKIGKRSAVED 
349 Feces   NTQSRRARRSASDS PQIGKRSAVED 
352 Feces   NTQSRRARRSASDS PQIGKRSAVED 
277.2 Feces  NHTQSRRSRRSTSDFV PTIGKRSAVED 
278 Feces  NHTQSRRVRRSVQESVQ PTIGKRSAIED 
BL1 Feces    THTRRSRRSAPA PTIGKRSAVED 
BL10 Feces    THTRRSRRSAPV PTIGKRSAVED 
BL11 Feces    THTRRSRRSAPV PTIGKRSAVED 
BL12 Feces    THTRRSRRSAPV PTIGKRSAVED 
BL13 Feces    THTRRSRRSAPV PTIGKRSAVED 
BL2 Feces    THTRRSRRSAPA PTIGKRSAVED 
BL3 Feces    THTRRSRRSAPA PTIGKRSAVED 
BL4 Feces    THTRRSRRSAPA PTIGKRSAVED 
BL5 Feces    THTRRSRRSAPV PTIGKRSAVED 
BL6 Feces    THTRRSRRSAPI PTIGKRSAVED 
BL7 Feces    THTRRSRRSAPI PTIGKRSAVED 
BL8 Feces    THTRRSRRSAPI PTIGKRSAVED 
BL9 Feces    THTRRSRRSAPA PTIGKRSAVED 
FECV-4582  Feces     TQQRRSRRSTSD PTIGKRSAVED 
FECV-4594  Feces    TQQRRSRRSTSD PTIGKRSAVED 
FECV-FCA4597 Feces    TQQRRSRRSTSD PTIGKRSAVED 
FECV-FCA4606  Feces    TQQRRSRRSTSD PTIGKRSAVED 	  	  	  	  
TABLE	  2	  	  	  	  	  Amino	  acid	  sequences	  in	  the	  S1/S2	  and	  S2'	  regions	  of	  the	  FCoV	  spike	  obtained	  from	  tissue	  and	  body	  fluid	  samples	  from	  cats	  diagnosed	  with	  FIP.	  	  The	  ten	  amino	  acids	  comprising	  the	  predicted	  proteolytic	  cleavage	  sites	  are	  in	  bold,	  with	  modification	  to	  these	  residues	  colored	  (red	  and	  blue	  =	  modification	  to	  core	  residue,	  green	  and	  violet	  =	  modification	  to	  non-­‐core	  residue).	  ND	  =	  not	  determined.	  	  
Cat ID Tissue       S1/S2 S2' 
129308 Mesentery    TSSRRSPRSTLD   not determined 
  Lower Gut    TSSRRSLRSTVR   not determined 
147 Blood    TQSRRARSSASD     PRIGERSAVED  
148 Ascites    TSSRRSRRPTTE     HSIGKRSAVED  
151643-08 Heart     TQFRRARRSAVR   not determined 
  Spleen     TQFRRSRRSTPG   not determined 
  Liver     TQFRRSRRSTVR   not determined 
157 Ascites  NHTQPRRARRSVSELV     PPSIGKRSAVED 
  Liver  NHTQPRRARRSVSELV     PPSIGKRSAVEDLLFN  
  Spleen  NHTQPRRARRSVSELV      PSIGKRSAVEDLLF 
  Spleen  NHTQPRRARRSVSELV     PPSIGKRSAVEDLLFN  
159 Ascites  NHTSSRRSRMSTPET    PPSIGKRSAVED 
162 Ascites  NHTQSRRSRRATSNP     PTTGKRSAVED 
163 Urinary Discharge  NHTQSRRSRMSTSDS     PPRVGKSSAIED 
166 Brain   HTHPRRSRGSTIETV    not determined  
170  Ascites    TQSRRSRRSTSD     PTIGKRSAVED  
 Liver    not determined     PTIGKRSAVED  
  Lung  NHTQSRRSRRSTSDFVT    PPTIGKRSAVEDLLFN  
179 Ascites  NHTQSRGSRRSTSD      PTIGKRSAVED  
181 Chest Fluid  NHTQSRRSRRSTSD     PPTIGKRSAVED  
  Liver VNHTQSRRSRRSTSD     PTIGKRSAVEDLLFN 
  Lung VNHTQSRRSRRSTSD     PTIGKRSAVEDLLFN 
  Spleen VNHTQSRRSRRSTSDF     PTIGKRSAVEDLLFN 
182 Ascites  NHTQSRSSRRSTPV     PPSIGKRSAVED  
192 Thoracic Fluid  NHTQSRRSRGSTSD     PPTIGKRSAVED  
195 Spinal Cord  NHTQSKTAPRGTSDSV   not determined 
   NHTQSKTAPRATSDS   not determined 
197 Ascites  NHTHSKRARWSTSD      PRIGMRSAIED 
  Kidney    THSRRSLRSAPV   not determined 
  Liver  NHTHSKRARWSTSDS    PPRIGMRSAIEDLLFN 
  Lung.1    THTRRSLRSAPD   not determined 
  Lung.2  NHTHSKRARWSTSDS    PPRIGMRSAIEDLLFN 
  Omentum  NHTHSKRARWSTSDS    PPRIGMRSAIEDLLFN 
  Small Intestine.1    THSRRSRRSASD   not determined 
  Small Intestine.2  NHTHSKRARWSTSDS    PPRIGMRSAIEDLLFN 
  Spleen  NHTHSKRARWSTSDS    PPRIGMRSAIEDLLFN 
211 Ascites  NHTHLRRSRRSTPE      RVGKRSAVED 
215 Ascites  NHTQSKSARRSTSD     PRIGKRSAIED 
232 Liver    TQSKSARRSTSD   not determined 
  Lung    TQSKSARRSTSD   not determined 
  Spinal Fluid  NHTQSKSARRSTSD     PRIGKRSAIED 
234 Kidney    THTRRSLRSAPV   not determined 
  Lung  NHTHTRRSLRSAPVA    PPTIGKRSAVEDLLF 
239 Blood  NHTQSKTARRSTSD     PRVGKSSAIED 
  Brain  NHTQSKTARRSTSDS     PPRVGKSSAIED 
   NHTQSKTALRSTSDS    not determined 
  Cerebellum  NHTQSKTALRSTSDSVI     PPRVGKSSAIED 
   NHTQSKTARRSTSDSVI   not determined 
  Cerebrum  NHTQSKTARRSTSDS    PPRVGKSSAIED 
  Kidney.1    THTRRSLRSAPV   not determined 
  Kidney.2  NHTQSKTARRSTSDS    PPRVGKSSAIED 
  Spleen  NHTQSKTARRSTSD    PPRVGKSSAIEDLLF 
241 Ascites  NYTHSRRSLSSTPE     PRIGKRSAVED 
244 Mesentery     HSRRASTSTSN   not determined 
  
Mesenteric lymph 
node    TQSRRASTSTSN   not determined 
245 Spinal Fluid  NHTQSRRSRRSKSN     PTVGKSSAVED 
    not determined      TVGKRSAVED 
256 Ascites  NHTHSKRARWSTSD     PRIGMRSAIED 
259 Brain  THTQSKSARRSTSDSVI          KRSAIED 
  Lung    TQSKSARRSTSD   not determined 
261 Liver    TQSRRMRRSTSN   not determined 
  Small Intestine    TRSRRMRRSTSN   not determined 
  Spleen    TQSRRMRRSTSN   not determined 
350 Kidney  NHTSARRSRRSASEII     PTIGKRSAVED 
  Lung VNHTSARRSRRSASEI     PTIGKRSAVED 
77 Kidney     THSRRSRMSTQN   not determined 
  Cerebellum.1    THSRRSLRSTQN    not determined 
  Cerebellum.2     THSRRSRRSTQN   not determined 
08-153990 Kidney     TQPRRARMSVPE   not determined 
  Cerebrum     TQPRRARMSVPE     PTIGMRSAVED  
  Brain stem     TQPRRAPMSVPE     PTIGMRSAVED  
  Cerebellum     TQPRRARMSVPE     PTIGMRSAVED  
N04-93 Kidney     THLRRSHRSTSE   not determined 
  Cerebrum     TLTGRSHRSTSE   not determined 
N05-48 Cerebellum     TQSRSSRRSTSD   not determined 
N05-110 
Mesenteric lymph 
node     TQTKRSRRSTPQ     PTIGKRSAVED  
  Cerebellum     TQTKRSRRSTPA   not determined 
N07-95 Cerebrum     THTRKTRRSIAD   not determined 
D04-397 Spleen     TQSRRSRRSTVD   not determined 
  
Mesentric lymph 
node     TQSRRSRRLTSN   not determined 
D06-327 Spleen     THSRRSRGSAPN   not determined 
  Mesentery     THSRRSRGSAPN   not determined 
429 Omentum    TSSRSSRRSTSE     SRIGERSAVED 
430 Omentum    SQSRRSRSSTSE     PRVGKRSAVED 	  	  	  
	  
	  	  	  	  
TABLE	  3	  	  	  	  	  Amino	  acid	  sequences	  in	  the	  S1/S2	  and	  S2'	  regions	  of	  the	  FCoV	  spike	  obtained	  from	  fecal	  	  samples	  from	  cats	  diagnosed	  with	  FIP.	  	  The	  ten	  animo	  acids	  comprising	  the	  predicted	  proteolytic	  cleavage	  sites	  are	  in	  bold,	  with	  modification	  to	  these	  residues	  colored	  (green	  =	  modification	  to	  non-­‐core	  residue).	  
Cat ID Sample      S1/S2     S2' 
107 Feces   TTSRRPRRSDPA PTIGKRSAVED 
108 Feces   QSSRRSRRSTSD PTIGKRSAVED  
145 Feces   THSRRARRSTVE PKIGKRSAVED 
148 Feces   TSSRRSRRSTTE PKIGKRSAVED 
215 Feces   THARRSRRSTPE PRIGKRSAIED 
251 Feces   TQSKRARRSTSD PRIGKRSAIED 
347 Feces   TRSRRSRRSTLEP PRVGKRSAVED 
352 Feces   TQSRRARRSASDS PQIGKRSAVED 	  
	  
TABLE	  4	  	  	  	  	  Amino	  acid	  sequences	  in	  the	  S1/S2	  and	  S2'	  regions	  of	  the	  FCoV	  spike	  obtained	  from	  Chang	  et	  al.	  and	  databases.	  	  The	  ten	  amino	  acids	  comprising	  the	  predicted	  proteolytic	  cleavage	  sites	  are	  in	  bold,	  with	  modification	  to	  these	  residues	  colored	  (red	  and	  blue	  =	  modifiation	  to	  core	  residue,	  green	  =	  modification	  to	  non-­‐core	  residue).	  Modifications	  that	  are	  not	  expected	  to	  be	  functionally	  relevent	  are	  shown	  in	  gray.	  n/a	  -­‐	  not	  applicable/unknown.	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SEQUENCE    
RM  n/a 
  
PRRSRRS      KRS 
 
FIPV   
Name Tissue    S1/S2 S2’ 
UU3  n/a   SRRSRRS      MRS 
UU4  n/a   SRSARGS      MRS 
UU5  n/a   SRRSRGS      KRS 
UU8  n/a   SRRSRRS      KRS 
UU9  n/a   SRRSRRL      KRS 
UU15  n/a   LRRSRRP      KRS 
UU16  n/a   PRGSRRS      MRS 
UU17  n/a   SRRSRRS      VRS 
UU21  n/a   SRRSRWS      MRS 
UU24  n/a   SRRSRSS      KRS 
UU30  n/a   LRRSRRS      KRS 
    
DATABASE SEQUENCES   
Black/TN406 Liver   AKRSRRP      VRS 
FCoV C1Je Jejunum 
  
PRQSRRS      KRS 
Q66951_9ALPC 
(KU-2)  n/a 
  
ARRSRSS      KRS 
Q8JVL1_9ALPC 
(Black/TN406)  n/a 
  
AKRSRRP      ARS 
Q8JVL2_9ALPC 
(UCD1)   n/a 
  





FIGURE	  1.	  	  Visual	  representation	  of	  amino	  acid	  properties	  in	  the	  S1/S2	  and	  S2’	  cleavage	  sites	  for	  FECV	  and	  FIPV.	  The	  Y-­‐axis	  is	  the	  Van	  der	  Waals	   volume	   (Å3),	   and	   the	  X-­‐axis	   is	   the	   hydropathy	   index	   (unitless).	   The	  data	   point	   size	   corresponds	   to	   the	   frequency	   of	  occurrence.	  Note	  that	  for	  FIPV,	  the	  frequency	  of	  occurrence	  is	  based	  on	  all	  samples	  collected	  and	  not	  just	  the	  number	  of	  FIP	  cats	  sampled.	  The	  table/legend	  summarizes	  all	  amino	  acid	  properties	  and	  color	  code.	  	  	  
	  
